Azienda Sanitaria Locale Roma 2
- Address
- lock Available on a paid plan
Azienda Sanitaria Locale Roma 2 - Hematologic Malignancies Research
Azienda Sanitaria Locale Roma 2 is a healthcare institution engaged in advancing treatment strategies for complex hematologic disorders. The center demonstrates specialized expertise in conducting pivotal Phase 3 clinical trials focused on myelodysplastic syndromes (MDS), particularly investigating innovative therapeutic combinations for patients with challenging disease presentations.
- Higher-risk myelodysplastic syndrome treatment optimization
- RARA-positive MDS targeted therapy development
- Novel combination regimens using azacitidine-based protocols
The center's research portfolio emphasizes precision medicine approaches in hematology, specifically targeting molecular markers such as RARA positivity to guide treatment selection. Through participation in multinational registration trials evaluating agents like tamibarotene in combination with established therapies, Azienda Sanitaria Locale Roma 2 contributes to expanding therapeutic options for newly diagnosed adult patients with higher-risk myelodysplastic syndromes and aims to improve complete remission rates in this challenging patient population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale Roma 2
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Randomized, Double-blind, Placebo-controlled Study of Tamibarotene and Azacitidine in RARA-positive Higher-risk Myelodysplastic Syndrome | Syros Pharmaceuticals Inc. | Phase III | Not Recruiting | — | Nov 2024 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azacitidine | 1 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.